Presse

Ferring Strich weiss
In diesem Bereich unserer Webseite finden Sie die neuesten nationalen und internationalen Pressemitteilungen der FERRING-Gruppe sowie eine Sammlung von Presseartikel über unsere innovativen Präparate aus den Bereichen Reproduktionsmedizin, Urologie, chronisch entzündliche Darmerkrankungen, Endokrinologie und Geburtshilfe.

Wenn Sie Journalist/-in sind und Fragen zu FERRING oder zu unseren Arzneimitteln haben, wenden Sie sich gerne direkt an uns:

Frau Dr. Sibille Engels 
FERRING Arzneimittel GmbH 
Tel.: +49 431 58 52 106 
Fax: +49 431 58 52 441 
E-Mail: info-service@ferring.de

Thursday, 13 May 2021

Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021

Read press release

 

Thursday, 18 Febuary 2021

Ferring appoints Jan Lundberg to Group Board

Read press release

 

Wednesday, 17 Febuary 2021

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

Read press release

 

Tuesday, 16 Febuary 2021

Simple Pharma acquires Testavan® and Vitaros®, two established men’s health brands, from Ferring

Read press release

 

Monday, 29 July 2020

Ferring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million

Read press release

 

Wednesday, 22 July 2020

Ferring appoints Mirjam Mol-Arts to Executive Committee 

Read press release

 

Wednesday, 04 June 2020

Ferring and Igenomix collaborate to advance care in reproductive medicine and maternal health

Read press release

 

Wednesday, 13 May 2020

Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births

Read press release

 

Wednesday, 06 May 2020

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

Read press release

 

Wednesday, 18 March 2020

Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine

Read press release

 

Tuesday, 04 Febuary 2020

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Thursday, 23 Janaury 2020

Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years



Ferring Widget Website


Presse-Archiv 2019

Lesen Sie hier unsere Pressemitteilungen aus dem Jahr 2019



Ferring Widget Website


Presse-Archiv 2018

Lesen Sie hier unsere Pressemitteilungen aus dem Jahr 2018



Ferring Widget Website


Presse-Archiv 2017

Lesen Sie hier unsere Pressemitteilungen aus dem Jahr 2017





Haben Sie Fragen?

Ferring Strich weissSchreiben Sie uns einfach an info-service@ferring.de.

FERRING – für Sie da.